drugset / Trial / NCT00680095

Cumulative Irritation Test

NCT00680095

Phase 1 Completed 37 enrolled Pfizer
Open-labelOther

Summary

The purpose of this study is to determine the cumulative irritation potential of the products listed by the Sponsor.

Timeline

Start
2007-01-22
Primary completion
2007-02-19
Completion
2007-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Lauryl Sulfate Small molecule 0.5 % Topical
Subject Tavaborole Small molecule 2.5 % Topical
Subject Tavaborole Small molecule 5 % Topical
Subject Tavaborole Small molecule 7.5 % Topical

Indications